Evolocumab · Repatha

Monoclonal antibody

Also known as AMG 145

Approvedregulatory verdict

Evidence outlook

Approved: Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
CN
  • New indication: adults with established atherosclerotic cardiovascular disease, to reduce the risk of myocardial infarction, stroke and coronary revascularization
  • Homozygous familial hypercholesterolemia in adults and adolescents over 12 years
Product first approved 2018amgen.com
JP
  • Familial hypercholesterolemia and hypercholesterolemia at high cardiovascular risk not adequately controlled by statins
Product first approved 2016biospace.com
CA
  • Prevention of Cardiovascular Events Repatha® (evolocumab injection) is indicated as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid- lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adult patients with atherosclerotic cardiovascular disease (ASCVD) by further lowering low-density lipoprotein cholesterol (LDL-C) levels (see 14 CLINICAL TRIALS). Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia [HeFH] and ASCVD)...
Product first approved 2015Health Canada
EU
  • Primary hypercholesterolaemia, mixed dyslipidaemia, homozygous familial hypercholesterolaemia; label now includes established atherosclerotic cardiovascular disease
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (35)
Atherosclerotic Cardiovascular Disease
NCT03689946 · Cedars-Sinai Medical Center
2019-03-19 – 2023-05-30 · Cardiovascular Disease, Hyperlipidemia
What this study did
NCT02867813 · Amgen
2016-09-02 – 2022-03-21 · Dyslipidemia
What this study did
NCT03080935 · Amgen
2017-03-13 – 2022-03-04 · Dyslipidemia
What this study did
NCT03570697 · Amgen
2018-11-19 – 2021-01-21 · Coronary Artery Disease (CAD)
What this study did
NCT03433755 · Amgen
2019-05-09 – 2020-05-09 · Primary Hypercholesterolemia, Mixed Dyslipidemia
What this study did
NCT02833844 · Amgen
2017-05-22 – 2020-01-27 · Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
What this study did
NCT03287609 · Insel Gruppe AG, University Hospital Bern
2018-01-23 – 2019-08-07 · Acute Coronary Syndrome
What this study did
NCT01854918 · Amgen
2013-04-23 – 2018-05-31 · Hyperlipidemia and Mixed Dyslipidemia
What this study did
NCT02634580 · Amgen
2016-02-27 – 2018-05-26 · Hypercholesterolemia
What this study did
NCT02729025 · Amgen
2016-04-14 – 2018-04-05 · Subjects With Hyperlipidemia, Dyslipidemia
What this study did
NCT02304484 · Amgen
2014-11-24 – 2018-03-09 · Hypercholesterolemia
What this study did
NCT03429998 · Hospital General Universitario Gregorio Marañon
2017-04-01 – 2018-01-28 · Hypercholesterolemia
What this study did
NCT02662569 · Amgen
2016-04-14 – 2017-12-06 · Diabetes, Hyperlipidemia, Mixed Dyslipidemia
What this study did
NCT01984424 · Amgen
2013-12-10 – 2017-11-21 · Hyperlipidemia
What this study did
NCT02739984 · Amgen
2016-05-17 – 2017-08-03 · Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
What this study did
NCT01813422 · Amgen
2013-04-18 – 2016-07-29 · Hypercholesterolemia
What this study did
NCT02189837 · Amgen
2014-07-08 – 2015-03-05 · Primary Hyperlipidemia and Mixed Dyslipidemia
What this study did
NCT01953328 · Amgen
2013-10 – 2014-06 · Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
What this study did
NCT01763905 · Amgen
2013-01-24 – 2013-11-19 · Hyperlipidemia
What this study did
NCT01879319 · Amgen
2013-07-11 – 2013-11-15 · Primary Hypercholesterolemia, Mixed Dyslipidemia
What this study did
NCT01849497 · Amgen
2013-04-18 – 2013-09-02 · Primary Hypercholesterolemia, Mixed Dyslipidemia
What this study did
Other / comorbidity
Evolocumab in STEMIactive not recruiting
NCT06081803 · Sejong General Hospital
2020-12-05 – 2025-12-31 · ST Elevation Myocardial Infarction
What this study did
NCT05741086 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2024-08-31 · Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis
What this study did
NCT03734211 · Lars Gullestad
2019-06-10 – 2023-05-20 · Cardiac Allograft Vasculopathy
What this study did
NCT04941105 · Collegium Medicum w Bydgoszczy
2021-06-01 – 2022-05-17 · Sars-CoV-2 Infection
What this study did
NCT04665830 · Hamid Al-Essa Organ Transplant Center
2018-05-01 – 2020-05-01 · Kideny Transplant Recipients With High Cardiovascular Risk Score
What this study did
Phase 2/3 (2)
Atherosclerotic Cardiovascular Disease
Homozygous Familial Hypercholesterolemia
Phase 2 (19)
Atherosclerotic Cardiovascular Disease
NCT06496243 · NewAmsterdam Pharma
2024-12-02 – 2027-02 · Dyslipidemias
What this study did
NCT06700720 · Beijing Inno Medicine Co., Ltd.
2026-02-25 – 2026-07-22 · Coronary Artery Disease, Coronary Atherosclerotic Disease
What this study did
NCT03515304 · Johns Hopkins University
2018-05-20 – 2025-03-25 · Acute Coronary Syndrome
What this study did
NCT04082442 · Johns Hopkins University
2019-09-01 – 2024-10-25 · Acute Coronary Syndrome
What this study did
NCT04338165 · University Hospital, Grenoble
2021-01-08 – 2022-11 · Atherosclerotic Cardiovascular Disease
What this study did
NCT03500302 · Johns Hopkins University
2018-05-04 – 2019-11-30 · Human Immunodeficiency Virus, Coronary Artery Disease
What this study did
NCT01439880 · Amgen
2011-10-07 – 2018-06-20 · Hypercholesterolemia
What this study did
NCT01652703 · Amgen
2012-07-10 – 2013-05-14 · Hypercholesterolemia and High Risk for Cardiovascular Events
What this study did
NCT01375751 · Amgen
2011-08-02 – 2012-05-16 · Hypercholesterolemia, Familial
What this study did
NCT01375764 · Amgen
2011-07-28 – 2012-05-08 · Hyperlipidemia
What this study did
Other / comorbidity
NCT06284564 · M.D. Anderson Cancer Center
2024-08-07 – 2028-10-01 · Metastatic Renal Cell Carcinoma
What this study did
NCT07301372 · The Affiliated Hospital of Xuzhou Medical University
2025-10-30 – 2026-06-01 · Acute Stroke
What this study did
NCT05144529 · Eziafa Oduah, MD, PhD, MPH
2022-03-22 – 2024-09-27 · Lung Cancer Metastatic
What this study did
NCT03944577 · University of Nebraska
2019-07-15 – 2023-03-28 · Heart Transplant
What this study did
NCT03791593 · Fundació Institut Germans Trias i Pujol
2018-12-03 – 2022-07-20 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT03869073 · University of British Columbia
2019-02-11 – 2021-02-11 · Sepsis
What this study did
NCT04303377 · Fondazione IRCCS Policlinico San Matteo di Pavia
2019-11-18 – 2020-07-24 · ST-elevation Myocardial Infarction
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04101643 · First Affiliated Hospital of Fujian Medical University
2019-09-29 – 2023-01-03 · Hereditary Spastic Paraplegia Type 5
What this study did
Phase 1 (8)
Atherosclerotic Cardiovascular Disease
NCT02275156 · Amgen
2014-08-19 – 2014-12-19 · Hyperlipidemia, Mixed Dyslipidemia
What this study did
Other / comorbidity
NCT06081153 · University of Pennsylvania
2026-12-01 – 2029-02-28 · Abdominal Aortic Aneurysm
What this study did
NCT07545226 · Amgen
2026-04-21 – 2026-09-08 · Healthy Participants
What this study did
NCT07422285 · Amgen
2026-01-16 – 2026-07-31 · Healthy Participants, Pharmacokinetics
What this study did
NCT06140095 · Region Stockholm
2024-02 – 2025-12 · Acute Metabolic Effects of Evolocumab and Atorvastatin
What this study did
NCT04937413 · Duke University
2021-10-08 – 2023-10-12 · Malignant Glioma, Glioblastoma
What this study did
NCT04189484 · Food and Drug Administration (FDA)
2020-01-07 – 2021-04-07 · Healthy Subjects, Pharmacokinetics, Pharmacodynamics
What this study did
Phase 4 (42)
Atherosclerotic Cardiovascular Disease
NCT07612774 · West China Hospital
2025-11-19 – 2029-12-31 · Coronary, Coronary Artery Disease
What this study did
NCT07803679 · Amgen
2027-01-31 – 2029-04-30 · Coronary Artery Disease, Hypercholesterolemia, Atheroma, Atherosclerotic Plaque
What this study did
NCT05976893 · Xiang Xie
2023-08-01 – 2025-12-31 · ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Cancer
What this study did
NCT04608474 · Brigham and Women's Hospital
2021-02-17 – 2025-05-14 · Hyperlipidemias
What this study did
NCT05661552 · Yonsei University
2022-12-01 – 2025-02-05 · Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
What this study did
NCT03900026 · Unity Health Toronto
2019-05-30 – 2025-01-30 · Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
What this study did
NCT05579418 · Hamad Medical Corporation
2022-11-01 – 2024-10-30 · STEMI, Dyslipidemias
What this study did
NCT05585151 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2022-11-09 – 2024-10-01 · Cerebral Atherosclerosis
What this study did
NCT05802108 · Zibo Central Hospital
2022-07-01 – 2024-06-30 · Adverse Effect of Cardiovascular Medications (Diagnosis)
What this study did
NCT04710368 · Annapoorna Kini
2021-05-04 – 2023-11-06 · Coronary Artery Disease
What this study did
NCT04100434 · Tianjin Chest Hospital
2021-01-01 – 2023-06-01 · Acute Coronary Syndrome, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
What this study did
NCT03851263 · ECRI bv
2019-08-30 – 2023-02-24 · Coronary Artery Disease
What this study did
NCT04073134 · Imperial College London
2019-09-11 – 2022-05-27 · Coronary Artery Disease, Atherosclerosis, Hyperlipidemias
What this study did
NCT04306471 · Leonardo Clavijo
2020-02-24 – 2022-02-04 · Critical Limb Ischemia
What this study did
NCT04659525 · Policlinico Casilino ASL RMB
2020-11-01 – 2021-12-30 · Hypercholesterolemia, CKD Stage 5, Chronic Kidney Disease Requiring Chronic Dialysis
What this study did
NCT04573777 · University of California, Los Angeles
2021-04-23 – 2021-12-16 · Ischemic Stroke
What this study did
NCT03932721 · University of Campinas, Brazil
2018-10-01 – 2021-10-30 · Dyslipidemia Associated With Type II Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension Arterial
What this study did
NCT04510844 · NYU Langone Health
2021-03-01 – 2021-10-01 · Chronic Kidney Diseases, High Cholesterol
What this study did
NCT03626831 · University of Erlangen-Nürnberg Medical School
2019-04-04 – 2021-07-12 · Atherosclerotic Cardiovascular Disease
What this study did
NCT04306081 · Leonardo Clavijo
2017-12-14 – 2021-03-30 · Peripheral Arterial Disease
What this study did
NCT03811223 · UMC Utrecht
2019-08 – 2021-03 · Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III
What this study did
NCT06231459 · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
2019-01-01 – 2020-12-31 · Hypercholesterolemia, Familial
What this study did
NCT04397653 · Policlinico Casilino ASL RMB
2020-05-04 – 2020-12-14 · Hypercholesterolemia, Chronic Kidney Disease Requiring Chronic Dialysis
What this study did
NCT03096288 · University of Florida
2017-10-03 – 2020-11-02 · Atherosclerotic Cardiovascular Disease
What this study did
NCT03331666 · Columbia University
2018-11-16 – 2020-02-04 · Familial Hypercholesterolemia
What this study did
NCT03258281 · Inova Health Care Services
2018-05-01 – 2019-10-01 · Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
What this study did
Homozygous Familial Hypercholesterolemia
NCT03403374 · Amgen
2018-08-04 – 2019-11-27 · Homozygous Familial Hypercholesterolemia HoFH
What this study did
Other / comorbidity
NCT04951856 · Assistance Publique - Hôpitaux de Paris
2021-09-29 – 2028-05-22 · STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
What this study did
NCT05152888 · Brigham and Women's Hospital
2022-03-03 – 2027-12-31 · Stable Coronary Disease
What this study did
NCT05641753 · NYU Langone Health
2022-12-06 – 2027-07-31 · Type 1 Diabetes
What this study did
NCT05284747 · Amgen
2022-10-26 – 2027-05-29 · Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
What this study did
NCT05613426 · Henan Institute of Cardiovascular Epidemiology
2023-04-03 – 2026-05-16 · ST Elevation Myocardial Infarction (STEMI)
What this study did
NCT07295366 · The Affiliated Hospital of Xuzhou Medical University
2025-12-20 – 2026-05-01 · Acute Stroke
What this study did
NCT05623995 · Lin Zhao
2022-12-15 – 2025-12-01 · In-stent Restenosis, Major Adverse Cardiovascular Events
What this study did
NCT05697185 · Second Affiliated Hospital of Guangxi Medical University
2023-02-01 – 2024-12-01 · Ischemic Stroke, Acute
What this study did
NCT03931161 · Imperial College Healthcare NHS Trust
2019-09-04 – 2024-05-06 · Carotid Artery Stenosis
What this study did
NCT04539223 · Canadian Medical and Surgical Knowledge Translation Research Group
2020-08-28 – 2022-05 · Carotid Artery Stenosis, Asymptomatic Carotid Artery Stenosis
What this study did
NCT04730973 · Azienda Ospedaliera Ordine Mauriziano di Torino
2021-03-01 – 2022-03-31 · Carotid Artery Disease
What this study did
NCT03829046 · Robert Rosenson
2019-06-03 – 2021-11-15 · Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction
What this study did
NCT02941016 · Copenhagen University Hospital, Rigshospitalet
2016-10 – 2020-10-01 · Lipid Lowering, Vascular Inflammation
What this study did
NCT02948777 · Marja-Riitta Taskinen
2016-10 – 2018-06 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (5)
Atherosclerotic Cardiovascular Disease
NCT07388420 · General Hospital of Shenyang Military Region
2026-01-02 – 2026-12-31 · Hypertriglyceridemia Induced Acute Pancreatitis
What this study did
NCT04141579 · Radboud University Medical Center
2020-11-10 – 2023-11-09 · Coronary Artery Disease, Atherosclerosis of Coronary Artery
What this study did
NCT05043740 · Second Xiangya Hospital of Central South University
2021-10 – 2023-10-01 · Acute Coronary Syndrome
What this study did
NCT04613167 · University Medical Centre Ljubljana
2020-11-10 – 2021-10-01 · Acute Coronary Syndrome, Premature Coronary Heart Disease, Lipoproteinemia, Inflammation, Genetic Polymorphisms
What this study did
Other / comorbidity
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Atherosclerotic Cardiovascular Disease
NCT04790513 · LIB Therapeutics LLC
2021-04-22 – 2022-12-31 · Hypercholesterolemia, Cardiovascular Diseases
What this study did
Homozygous Familial Hypercholesterolemia
NCT04034485 · LIB Therapeutics LLC
2019-12-07 – 2023-01-30 · Homozygous Familial Hypercholesterolemia
What this study did
Phase 2 (2)
Atherosclerotic Cardiovascular Disease
NCT04992065 · Novo Nordisk A/S
2021-08-03 – 2022-06-20 · Atherosclerotic Cardiovascular Disease
What this study did
NCT03060577 · Novartis Pharmaceuticals
2017-04-27 – 2021-12-17 · Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Atherosclerotic Cardiovascular Disease
NCT02585895 · Amgen
2015-12-21 – 2017-01-20 · Hypercholesterolemia
What this study did
Phase 2 (1)
Atherosclerotic Cardiovascular Disease
NCT03193047 · Esperion Therapeutics, Inc.
2017-04-07 – 2018-02-19 · Hypercholesterolemia
What this study did
Early phase / not applicable (1)
Atherosclerotic Cardiovascular Disease
NCT05587621 · Jena University Hospital
2024-04-01 – 2026-12-31 · ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
What this study did

Competitive landscape

This mechanism is crowded: 19 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Evolocumab (Repatha): this drugApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
BW-20829Phase 2RNA / oligonucleotideLipoprotein(a) [Lp(a)] production pathwaynot yet gradedNo reviewed efficacy summary in this indication
CNIC-Ferrer Polypill (Trinomia)Phase 2Small moleculeMulti-mechanism secondary-prevention polypillPartial signalNo reviewed efficacy summary in this indication
DNV001Phase 2RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3Weak signalNo reviewed efficacy summary in this indication
EtribnabdionePhase 2—CB2 receptor and PPARγ (dual agonist)not yet gradedNo reviewed efficacy summary in this indication
HRS-1301Phase 2Small moleculePCSK9Weak signalNo reviewed efficacy summary in this indication
HRS-5346Phase 2Small moleculeLipoprotein(a) [Lp(a)] formationPartial signalNo reviewed efficacy summary in this indication
HRS-5632Phase 2Unknown/UndisclosedLipoprotein(a)Weak signalNo reviewed efficacy summary in this indication
Human Acellular Vessel (Humacyte)Phase 2Tissue-engineered Vessel (bioengineered)tissue-engineered acellular vascular graftWeak signal
NCT01872208: Primary patency 58%, primary-assisted patency 58%, secondary patency 74% at 24 months (Kaplan-Meier estimate, n=20)
Kylo-11Phase 2RNA / oligonucleotideLipoprotein(a)not yet gradedNo reviewed efficacy summary in this indication
OrticumabPhase 2Monoclonal antibodyOxidized low-density lipoprotein (oxLDL) epitopePartial signalNo reviewed efficacy summary in this indication
SAL0137Phase 2Small moleculeApolipoprotein(a) [apo(a)] / apo(a)-apoB100 interactionnot yet gradedNo reviewed efficacy summary in this indication
SelnoflastPhase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
COR-1004Phase 1—PCSK9not yet gradedNo reviewed efficacy summary in this indication
HS-10510Phase 1Small moleculePCSK9not yet gradedNo reviewed efficacy summary in this indication
RBD7022Phase 1RNA / oligonucleotidePCSK9Weak signalFeatured results are safety only in this race
RN0191Phase 1RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
AZD8233DiscontinuedRNA / oligonucleotidePCSK9Partial signalFeatured results are safety only in this race

Large race: only the 79 furthest-along competitors are listed; 44 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Repatha (Evolocumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-11 · NCT06496243 · CT.gov ↗
What to watch
December 2026 (1)
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT07388420 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Phase 4Stable Coronary DiseaseRecruiting
Est. primary completion 2027-03-31 · NCT05152888 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary RevascularizationActive not recruiting
Est. primary completion 2027-05-29 · NCT05284747 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Type 1 DiabetesRecruiting
Est. primary completion 2027-07-01 · NCT05641753 · CT.gov ↗
What to watch
2028 (2)
October 2028 (2)
Phase 2Metastatic Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-10-01 · NCT06284564 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-10-31 · NCT07612774 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 1Abdominal Aortic AneurysmNot yet recruiting
Est. primary completion 2029-01-15 · NCT06081153 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2029-04-30 · NCT07803679 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2025Topline resultVESALIUS-CV Phase 3 met dual primary endpoints